Eli Lilly to Buy Centessa Pharmaceuticals for Up to $7.8bn in Neuro Push
NEW YORK, April 1 -
Eli Lilly agreed to acquire Centessa Pharmaceuticals plc (CNTA) for up to $7.8bn, paying $6.3bn upfront to get the biotech's orexin receptor pipeline.
- Total deal value: up to $7.8bn, with $6.3bn in upfront cash and the remainder in contingent value rights
- CNTA shares hit an all-time high post-announcement but still trade at a ~38% discount to the full deal price
- Two hurdles remain: regulatory and antitrust clearance, plus CVR milestone triggers that unlock the remaining $1.5bn
What Actually Happened
Lilly just wrote a $6.3bn check for a company with $15 million in trailing revenue. Read that again. That's roughly 420x sales. the kind of multiple you pay when you're not buying a business, you're buying a shortcut. Centessa's orexin receptor agonists target sleep-wake disorders, a category where patient demand is surging and the competitive field is almost comically thin. Lilly looked at its internal neuroscience timeline, did the math, and decided years of R&D risk cost more than $7.8bn in certainty. a classic build-vs-buy calculus that tells you exactly how valuable this mechanism is to Big Pharma portfolios.
For CNTA shareholders, the economics are almost absurd. A forward P/E of -24.2x confirms what everyone already knew: this is a pre-revenue biotech being valued entirely on clinical-stage promise. Think of it like buying a house based on the architect's rendering. Lilly is paying finished-home prices for a foundation and some very impressive blueprints. Options volume has exploded as arb desks pile into the gap between the current $39.72 share price and the implied full deal value, making CNTA one of the most actively traded merger-arb setups in biotech right now.
Here's the part worth staring at: the ~38% discount to the full $7.8bn consideration is roughly double the spread on recent pharma takeouts. That's not noise. The market is telling you it sees two distinct risk layers. regulatory approval and CVR milestone achievement. and is pricing both as genuinely uncertain. Anyone buying here is making a compound bet, and compound bets have a way of disappointing on at least one leg.
The Catch
The deal structure is a feature, not a bug. for Lilly. That $1.5bn in CVRs is contingent on specific clinical and commercial milestones, which means Lilly capped its downside while CNTA holders who sell at market forfeit the upside forever. If regulators block the deal, the merger premium evaporates overnight. If the pipeline stumbles post-close, Lilly eats the write-down but CVR holders get nothing. A competing bid could reset the math, but realistically, few acquirers can match Lilly's balance sheet in this therapeutic area. making the current offer a take-it-or-leave-it proposition for most shareholders.
Bottom Line
This deal is a referendum on orexin's commercial potential. The $6.3bn upfront says Lilly believes it; the 38% spread says the market wants proof. For merger-arb traders, the risk-reward hinges entirely on regulatory timing and pipeline readouts. For everyone else, the real signal is strategic: when the world's most valuable pharma company pays 420x revenue for a neuroscience asset, it reprices every comparable pipeline in the space.
Centessa Pharmaceuticals does not yet have a dedicated research page on Basis Report. visit the CNTA stock page to generate a full analysis including pipeline valuation and deal-spread tracking.
Basis Report does not hold positions in securities discussed. This is not investment advice.